403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

November 7, 2007 at 5:18 PM

Potential rival to Enbrel on the horizon

An experimental arthritis therapy known as golimumab showed promising results in a late-stage clinical study for the treatment of psoriatic arthritis, Johnson & Johnson unit Centocor and Schering-Plough said Wednesday. The data signals the potential appearance of a new rival to Enbrel, the best-selling treatment developed in Seattle by Immunex and now sold by Amgen.

The compound is designed to be administered less frequently than Enbrel and Abbott Laboratories’ Humira (one injection a month, instead of one a week for Enbrel and one every two weeks for Humira). The therapy constitutes an “incremental improvement” over Enbrel and other similar drugs, said Dr. Philip Mease, chief of the Swedish Medical Center’s Division of Rheumathology Research in Seattle. Dr. Mease served as an investigator in the trial.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx